AUG 10, 2020 8:18 AM PDT

A New Prognostic Biomarker for Paclitaxel Sensitivity in Breast Cancer

WRITTEN BY: Jasper Cantrell

Breast cancer is one of the deadliest cancers globally. It has been studied extensively with plenty of treatments available. Cancers tend to have subtle characteristics that can make them resistant or sensitive to one form of treatment or another. The key to modern therapy lies in identifying which treatment works best for each patient.

Paclitaxel is a chemotherapy drug that targets the microtubules in a cell and is a first-line treatment for many cancers. Microtubules are an essential component of a cell’s skeleton and play a role in cellular division. Paclitaxel prevents microtubules from functioning properly and is a proven chemotherapy. Unfortunately, it is only effective in 20% of breast cancer patients. Identifying which patients would react favorably to paclitaxel and other such therapies is critical and could cut down on costly ineffective treatment choices.

A team from the Universite Paris-Saclay in France had tackled this problem before and identified the protein ATIP3 as a biomarker to predict if a breast cancer patient has a taxane sensitive tumor. ATIP3 is a protein involved in microtubule stabilization. When levels were low in a cancer, it was paclitaxel sensitive, although it had a more aggressive nature. In a new study, they investigated why low ATIP3 levels were a marker of paclitaxel sensitivity.

They began by examining how taxane-based chemotherapy affected a cohort of breast cancer patients. ATIP3 deficient patients had decreased metastasis after treatment, compared to others of the cohort that showed no change in metastasis post-treatment. Cell assays found that ATIP3 managed to improve paclitaxel’s anti-metastatic activity by increasing paclitaxel accumulation within the cell itself.

This study managed to identify that ATIP3 deficiency caused paclitaxel to accumulate in cells. They note that other studies have seen similar results with other microtubule destabilizers. One group even showed that the addition of a destabilizer could increase paclitaxel’s effectiveness in vitro. What makes ATIP3 deficiency unique is that it can be tested for, making it a potential biomarker for taxane sensitive breast cancers.

The study concludes, “we show here that ATIP3 deficiency in breast cancer facilitates paclitaxel accumulation on the microtubule lattice of interphase cells, and improves the anti-migratory and anti-metastatic effects of the drug.” With further validation, ATIP3 testing could give patients more options for a tailored therapy that is right for them.

Sources: Nature Scientific Reports, OncLiveTV

 

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
MAY 10, 2021
Cell & Molecular Biology
Getting RNA-Based Medicine Past the Blood-Brain Barrier
MAY 10, 2021
Getting RNA-Based Medicine Past the Blood-Brain Barrier
RNA molecules serve several functions, one of which is to help the cell generate proteins from active genes. It also may ...
MAY 18, 2021
Cancer
New guidelines change screening age for colorectal cancer to 45
MAY 18, 2021
New guidelines change screening age for colorectal cancer to 45
Following new guideline changes from the U.S. Preventive Services Task Force (USPSTF), individuals with an average risk ...
JUN 23, 2021
Cancer
Military universal health system boasts higher survival rates for colon cancer patients
JUN 23, 2021
Military universal health system boasts higher survival rates for colon cancer patients
New results published in the American Association for Cancer Research journal Cancer Epidemiology, Biomarkers & Prev ...
JUL 30, 2021
Cancer
Obesity Reduces Mortality in Advanced Prostate Cancer
JUL 30, 2021
Obesity Reduces Mortality in Advanced Prostate Cancer
Obese patients with an advanced form of prostate cancer survive longer than their slimmer counterparts, according to res ...
AUG 25, 2021
Cell & Molecular Biology
Sino Biological's Listing on the Shenzhen Stock Exchange
AUG 25, 2021
Sino Biological's Listing on the Shenzhen Stock Exchange
China, August 16, 2021 - Sino Biological, Inc. (“Sino Biological” or the “Company”), a biot ...
AUG 25, 2021
Chemistry & Physics
Self-Assembling Molecules: A Potential "One-Size-Fits-All" Cancer Therapy
AUG 25, 2021
Self-Assembling Molecules: A Potential "One-Size-Fits-All" Cancer Therapy
A new study from the University of Huddersfield shows promising breakthroughs on the use of self-assembling molecules as ...
Loading Comments...